Kishi H, Kishi T, Williams R H, Watanabe T, Folkers K, Stahl M L
Res Commun Chem Pathol Pharmacol. 1977 Jun;17(2):283-93.
The specific activities (S.A.) of the glutamic oxaloacetic transaminase from erythrocytes (EGOT) of 75 women taking 16 diversified contraceptive formulations were determined by the principle (CAS) of unsaturation and saturation of receptors of the Coenzyme-Apoenzyme-System with the coenzyme, pyridoxal 5'-phosphate. 52 women were not taking pyridoxine; 20 were taking 1-5 mg; 3 were taking 25-100 mg. The mean basal S.A. of the 52 women without pyridoxine was lower (p less than 0.01) than for the 20 on 1-5 mg. The mean basal S.A. for the women on 25-100 mg was higher (p less than 0.01) than for the women without pyridoxine. The mean % deficiency for the women on 25-100 mg was negligible and lower (p less than 0.01) than 18+/-8 for the 52 women, and 14+/-6 for the 20 women. These data indicate that 1-5 mg of pyridoxine is inadequate for women on contraceptives. The requisite daily dosage is projected at 50-100 mg. Other data indicate that 5-12 weeks of supplementation with pyridoxine can be required to reach a stable "ceiling" of S.A. of EGOT. This period indicates some regulatory mechanism by diminished levels of the apoenzyme upon gene expression to bring about normal levels of the transaminase.
采用辅酶 - 脱辅酶系统的受体与辅酶磷酸吡哆醛的不饱和及饱和原理（CAS），测定了75名服用16种不同避孕药制剂的女性红细胞谷草转氨酶（EGOT）的比活性（S.A.）。52名女性未服用吡哆醇；20名女性服用1 - 5毫克；3名女性服用25 - 100毫克。52名未服用吡哆醇女性的平均基础S.A.低于服用1 - 5毫克的20名女性（p小于0.01）。服用25 - 100毫克的女性平均基础S.A.高于未服用吡哆醇的女性（p小于0.01）。服用25 - 100毫克的女性平均缺乏百分比可忽略不计，且低于52名女性的18±8以及20名女性的14±6（p小于0.01）。这些数据表明，对于服用避孕药的女性，1 - 5毫克的吡哆醇剂量不足。预计每日所需剂量为50 - 100毫克。其他数据表明，可能需要5 - 12周的吡哆醇补充才能达到EGOT的S.A.稳定“上限”。这一时期表明存在某种调节机制，即基因表达时脱辅酶水平降低，从而使转氨酶达到正常水平。
